Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the trial miss was a significant setback that could curb demand for CagriSema, temper long-term sales hopes and leave Novo struggling to win back share in the fast-growing obesity treatment market."
— J.P. Morgan analysts , Executive
"Sigo siendo muy optimista con respecto a CagriSema."
— Mike Doustdar , Executive
Key People
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaTdmamc4QU9IekYyT2hOdlVOdlowVjFnZE84b29mN3RuNXFUMURRaUEwTUkzMEwxVllJT3NzdHo3ZjNoYmJmZk41QUpkSTRacmdCd2ZpSVkxdE1icFVXUVVOVUExblRobUpuT2FUSV8td3dCUS00dm5NYU5LYmFTTEdLT0lhQm9naEczT2lySU9GSS1ZUFpEZnNCemFVUk9lejMxR2RBVFNScFBRamlpbEpjQU1iX0RmVjlJVXZJR0k2T2dGZkJWVWItaDY4czE3YkdTT1Fab05tUQ?oc=5" target="_blank">Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out</a> <font color="#6f6f6f">Reuters</font>
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy’s launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly’s tirzepatide in a trial.
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk ha sufrido una nueva caída en Bolsa tras anunciar que los ensayos clínicos de su nuevo medicamento contra la obesidad, CagriSema, no alcanzaron el criterio principal de efectividad frente a su competidor Tirzepatida, comercializado por Eli Lilly.
Similar Stories
Related coverage based on topic and tags
China's drug regulator accepts Novo Nordisk's application for oral Wegovy - Reuters
China's drug regulator accepts Novo Nordisk's application for oral Wegovy Reuters
August 27, 2026 at 03:47 AMMarvell raises annual forecasts, but shares fall as Google deal questions linger - Reuters
Marvell raises annual forecasts, but shares fall as Google deal questions linger Reuters
August 27, 2026 at 11:10 PMNvidia shares set for $280 billion price swing after earnings, options show - Reuters
Nvidia shares set for $280 billion price swing after earnings, options show Reuters
August 25, 2026 at 05:01 AMMore US employers to drop weight-loss drugs in 2027, as healthcare costs increase - Reuters
More US employers to drop weight-loss drugs in 2027, as healthcare costs increase Reuters
August 25, 2026 at 03:46 PMBest Buy's stronger forecast fails to reassure investors; shares fall - Reuters
Best Buy's stronger forecast fails to reassure investors; shares fall Reuters
August 27, 2026 at 04:41 PMPayPal shares sink on reports Advent-Stripe consortium walks away from bid - Reuters
PayPal shares sink on reports Advent-Stripe consortium walks away from bid Reuters
August 28, 2026 at 05:12 PM